Quantum BioPharma is trading 5% down at $3.40 after opening amid broader market weakness and ahead of inflation-sensitive trading.
- No new company-specific announcement was identified for September 10, 2026; the latest reported catalyst was FDA clearance to begin a Phase 2 Lucid-MS trial, announced September 9, 2026.
- Shares gained 8.81% to $3.58 on September 9, 2026, suggesting profit-taking may also be contributing.
- Major indexes were down less than 0.5% in the supplied market context, leaving the precise catalyst unclear.